NZ773036A - Anti-gdf15 antibodies, compositions and methods of use - Google Patents

Anti-gdf15 antibodies, compositions and methods of use

Info

Publication number
NZ773036A
NZ773036A NZ773036A NZ77303619A NZ773036A NZ 773036 A NZ773036 A NZ 773036A NZ 773036 A NZ773036 A NZ 773036A NZ 77303619 A NZ77303619 A NZ 77303619A NZ 773036 A NZ773036 A NZ 773036A
Authority
NZ
New Zealand
Prior art keywords
acid sequence
seq
lcdr
hcdr
nucleic acid
Prior art date
Application number
NZ773036A
Other versions
NZ773036B2 (en
Inventor
Kevin Charles Beaumont
Danna M Breen
Jeffrey Raymond Chabot
Tao He
Ksenya Shchors
James R Apgar
Matthew Allister Lambert
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=69232873&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ773036(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of NZ773036A publication Critical patent/NZ773036A/en
Publication of NZ773036B2 publication Critical patent/NZ773036B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to GDF15, as well as methods and uses for the antibodies.

Claims (23)

1. An antibody, or antigen binding fragment thereof, that specifically binds to human growth differentiation factor 15 (GDF15), comprising: a light chain complementarity determining region 5 1 (LCDR-1) comprising the amino acid sequence of SEQ ID NO:95, a LCDR-2 comprising the amino acid sequence of SEQ ID NO:28, a LCDR-3 comprising the amino acid sequence of SEQ ID NO:9, a heavy chain complementarity determining region 1 (HCDR-1) comprising the amino acid sequence of SEQ ID NO:32, a HCDR-2 comprising the amino acid sequence of SEQ ID NO:165, and a HCDR-3 comprising the amino acid sequence of SEQ ID NO:52.
2. An antibody, or antigen binding fragment thereof, that specifically binds to human GDF15, comprising a HCDR-1, a HCDR-2, and a HCDR-3 of a heavy chain variable domain (VH) having the amino acid sequence of SEQ ID NO:166, and a LCDR-1, a LCDR-2, and a LCDR-3 of a light chain variable domain (VL) having the amino acid sequence of SEQ ID NO:163, wherein (i) 15 each of the HCDR-1, HCDR-2, HCDR-3, LCDR-1, LCDR-2, and LCDR-3 is defined in accordance with Kabat definitions, (ii) each of the HCDR-1, HCDR-2, HCDR-3, LCDR-1, LCDR- 2, and LCDR-3 is defined in accordance with Chothia definitions, (iii) each of the HCDR-1, HCDR-2, HCDR-3, LCDR-1, LCDR-2, and LCDR-3 is defined in accordance with extended definitions, or (iv) each the HCDR-1, HCDR-2, HCDR-3, LCDR-1, LCDR-2, and LCDR-3 is 20 defined in accordance with AbM definitions.
3. An antibody that specifically binds to human GDF15, comprising a VH comprising the amino acid sequence encoded by the insert of the plasmid deposited at the ATCC and having ATCC Accession No. PTA-125038, and a VL comprising the amino acid sequence encoded by the 25 insert of the plasmid deposited at the ATCC and having ATCC Accession No. PTA-125039.
4. An antibody that specifically binds to human GDF15, comprising a VH comprising the amino acid sequence of SEQ ID NO:166 and a VL comprising the amino acid sequence of SEQ ID NO:163.
5. The antibody of any one of claims 1 - 4, comprising a human Fc domain selected from the group consisting of an Fc domain of IgA IgA , IgD, IgE, IgM, IgG , IgG , IgG , or IgG . 1 2 1 2 3 4
6. An antibody that specifically binds to human GDF15, comprising a HC comprising the amino acid sequence of SEQ ID NO:164, and a LC comprising the amino acid sequence of SEQ ID
7. NO:162. 5 7. The antibody, or antigen binding fragment thereof, of any one of claims 1 - 6, wherein the antibody, or antigen binding fragment thereof, binds human or cynomolgus monkey GDF15 with a K about or less than a value selected from the group consisting of about 10nM, 5nM, 2nM, 1nM, 900pM, 800pM, 700pM, 600pM, 500pM, 400pM, 300pM, 250pM, 200pM, 150pM, 100pM, 50pM, 40pM, 30pM, 25pM, 20pM, 15pM, and 10pM.
8. An isolated nucleic acid encoding the antibody, or antigen-binding portion thereof, of any one of claims 1 – 7.
9. An isolated nucleic acid comprising: 15 a) the nucleic acid sequence of SEQ ID NO:167, the nucleic acid sequence of SEQ ID NO:168, or both, b) the nucleic acid sequence of SEQ ID NO:169, the nucleic acid sequence of SEQ ID NO:170, or both, or c) the nucleic acid sequence of the insert of the plasmid deposited with the ATCC and 20 having the Accession Number PTA-125038, the nucleic acid sequence of the insert of the plasmid deposited with the ATCC and having the Accession Number PTA- 125039, or both.
10. A vector comprising the nucleic acid of claim 8 or 9.
11. A host cell comprising the vector of claim 10, wherein the host cell is not within a human.
12. The host cell of claim 11, wherein said host cell is a mammalian cell selected from the group consisting of a CHO cell, a COS cell, a HEK-293 cell, an NS0 cell, a PER.C6® cell, or an 30 Sp2.0 cell.
13. A method of making an antibody, or antigen binding fragment thereof, comprising culturing a host cell comprising a vector comprising (i) the nucleic acid of claim 8, (ii) the nucleic acid sequence of SEQ ID NO:167 and the nucleic acid sequence of SEQ ID NO:168, (iii) the nucleic acid sequence of SEQ ID NO:169, and the nucleic acid sequence of SEQ ID NO:170; or (iv) the nucleic acid sequence of the insert of the plasmid deposited with the ATCC and having the Accession Number PTA-125038, and the nucleic acid sequence of the insert of the plasmid deposited with the ATCC and having the Accession Number PTA-125039, under a condition 5 wherein said antibody, or antigen binding fragment thereof, is expressed by said host cell.
14. A pharmaceutical composition comprising an antibody, or antigen binding fragment thereof, of any one of claims 1 – 7, and a pharmaceutically acceptable carrier or excipient. 10
15. Use of the antibody, or antigen binding fragment thereof, of any one of claims 1 -8 or the pharmaceutical composition of claim 15 in the manufacture of a medicament for treating a medical condition, disease or disorder mediated by or associated with expression of GDF15.
16. The use of claim 15, wherein the condition is cachexia associated with cancer, 15 chemotherapy, chemotherapy in combination with an immuno-oncology therapy, chronic obstructive pulmonary disease, chronic kidney disease, chronic heart failure, congestive heart failure, or sarcopenia.
17. The antibody, or antigen binding fragment thereof, of any one of claims 1-4 and 6, 20 substantially as herein described with reference to any example thereof and with or without reference to any one or more of the accompanying figures.
18. The isolated nucleic acid of claim 8 or 9, substantially as herein described with reference to any example thereof and with or without reference to any one or more of the accompanying 25 figures.
19. The vector of claim 10, substantially as herein described with reference to any example thereof and with or without reference to any one or more of the accompanying figures. 30
20. The host cell of claim 11, substantially as herein described with reference to any example thereof and with or without reference to any one or more of the accompanying figures.
21. The method of claim 13, substantially as herein described with reference to any example thereof and with or without reference to any one or more of the accompanying figures.
22. The pharmaceutical composition of claim 14, substantially as herein described with reference to any example thereof and with or without reference to any one or more of the accompanying figures.
23. The use of claim 15, substantially as herein described with reference to any example thereof and with or without reference to any one or more of the accompanying figures
NZ773036A 2019-08-15 Anti-gdf15 antibodies, compositions and methods of use NZ773036B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862765289P 2018-08-20 2018-08-20
US201862750479P 2018-10-25 2018-10-25
US201862750393P 2018-10-25 2018-10-25
US201962881064P 2019-07-31 2019-07-31
PCT/IB2019/056932 WO2020039321A2 (en) 2018-08-20 2019-08-15 Anti-gdf15 antibodies, compositions and methods of use

Publications (2)

Publication Number Publication Date
NZ773036A true NZ773036A (en) 2025-03-28
NZ773036B2 NZ773036B2 (en) 2025-07-01

Family

ID=

Also Published As

Publication number Publication date
PH12021550337A1 (en) 2021-10-04
JP7155403B2 (en) 2022-10-18
EP3841121A2 (en) 2021-06-30
SG11202101502YA (en) 2021-03-30
MX427271B (en) 2025-10-13
AU2019323790B2 (en) 2026-01-29
AU2019323790A1 (en) 2021-03-11
MX2021001841A (en) 2021-05-13
TW202021619A (en) 2020-06-16
WO2020039321A8 (en) 2020-10-01
JP2022188191A (en) 2022-12-20
US20250326829A1 (en) 2025-10-23
US12227564B2 (en) 2025-02-18
PE20211412A1 (en) 2021-08-02
CN112912395A (en) 2021-06-04
WO2020039321A2 (en) 2020-02-27
KR20210049840A (en) 2021-05-06
US20220380448A1 (en) 2022-12-01
JP2021526847A (en) 2021-10-11
BR112021003173A2 (en) 2021-05-11
CO2021001893A2 (en) 2021-03-08
TWI803682B (en) 2023-06-01
KR102715542B1 (en) 2024-10-08
IL280963A (en) 2021-04-29
CN112912395B (en) 2024-08-23
WO2020039321A3 (en) 2020-05-07
US11566066B2 (en) 2023-01-31
US20200055930A1 (en) 2020-02-20
CA3109905A1 (en) 2020-02-27
MY205789A (en) 2024-11-13

Similar Documents

Publication Publication Date Title
US20250313634A1 (en) Novel anti-pd-l1 antibodies
CN106831996B (en) Bispecific antibody with CD3E and/or HER2 targeting function and use thereof
CN109963876B (en) Anti-PD-1/anti-HER2 natural antibody structure-like heterodimer form bispecific antibody and its preparation
CN116848134A (en) Multispecific antibodies specific for IL-4R and IL-31
RU2019140602A (en) ANTI-GARP-TGF-β-ANTIBODIES
CN106459212A (en) Antibodies that bind ERBB‑2 and ERBB‑3
RU2015144105A (en) ANTIBODIES TO HEPSIDINE AND THEIR APPLICATION
CN111201238B (en) Generation of multispecific antibody mixtures and methods of use
WO2021218684A1 (en) Tetravalent bispecific antibody, preparation method therefor, and use thereof
CA3097414A1 (en) Monoclonal antibody against nerve growth factor, and encoding gene and use thereof
US12173081B2 (en) CD19/CD38 multispecific antibodies
JP2024024114A5 (en)
CN116848135A (en) Novel anti-GREMLIN1 antibodies
EP4663660A1 (en) Trispecific antigen-binding molecule and use thereof
WO2023000791A1 (en) Antibodies against ror1 and uses thereof
WO2023028162A1 (en) Antibodies targeting immunosuppressive b cells
EP4392062A1 (en) Methods of treating cancers associated with immunosuppressive b cells
NZ773036B2 (en) Anti-gdf15 antibodies, compositions and methods of use
JP2024123082A (en) Bispecific antibodies or antigen-binding fragments thereof and methods for producing same
CN107249630A (en) Treatment of acute exacerbations of chronic obstructive pulmonary disease by IL‑20R antagonism
CN120271706A (en) Anti-EGFR monoclonal antibodies, bispecific antibodies, pharmaceutical compositions and uses
CN113461817B (en) Anti-human CD47 antibody and antigen-binding fragment thereof, preparation method and application
WO2024088342A1 (en) Antibodies against cd24 and uses thereof
CN116715769B (en) Anti-HVEM antibody, preparation method and use thereof
HK40093421A (en) Novel anti-gremlin1 antibodies

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 AUG 2026 BY THOMSON REUTERS

Effective date: 20250701